HMGN2: A Protein That Regulates Chromatin Structure and Gene Expression

Target Name: HMGN2

NCBI ID: G3151

HMGN2

HMGN2: A Protein That Regulates Chromatin Structure and Gene Expression

HMGN2, also known as high mobility group nucleosome-binding domain-containing protein 2, is a protein that plays a crucial role in the regulation of chromatin structure and gene expression. It is a member of the HMGN family, which consists of a group of proteins that share a common domain called the high mobility group (HMG) domain. The HMG domain is a structural feature that is found in a variety of proteins that plays a key role in the regulation of protein stability and localization.

HMGN2 is a non-coding protein that is expressed in a variety of tissues, including the brain, heart, and gastrointestinal tract. It is primarily localized to the nucleosome, which is the basic unit of chromatin. The nucleosome is a complex structure that consists of a core of DNA, a protein cap at the top, and a series of histone proteins that help to keep the DNA package together.

The HMG domain is a structural feature that is found in a variety of proteins that plays a key role in the regulation of protein stability and localization. It is a small protein that is composed of 24 amino acid residues. It has a characteristic Rossmann-fold, which is a type of hydrogen bonding that helps to hold the protein together.

One of the functions of HMGN2 is to interact with the nucleosome. The nucleosome is the basic unit of chromatin, and it is composed of a core of DNA, a protein cap at the top, and a series of histone proteins that help to keep the DNA package together. The HMG domain of HMGN2 is able to interact with the nucleosome, helping to regulate the stability of chromatin.

In addition to its role in regulating chromatin structure, HMGN2 is also involved in the regulation of gene expression. It is a regulator of DNA binding, which means that it is able to interact with the DNA and help to determine where DNA is bound. This is important because the binding of DNA to RNA is a critical step in gene expression.

HMGN2 is also involved in the regulation of cell signaling pathways. It is a regulator of the PI3K/Akt signaling pathway, which is a pathway that is involved in the regulation of cell growth and differentiation. This is important because the PI3K/Akt signaling pathway is involved in the regulation of many cellular processes, including cell signaling, cell migration, and cell survival.

Despite its importance, HMGN2 is not well understood. There are currently no known drugs that are specifically targeting HMGN2. This is because the study of protein-protein interactions is an important area of research, and it is difficult to study. However, new studies are being done to better understand the role of HMGN2 in the regulation of chromatin structure and gene expression.

Conclusion

HMGN2 is a non-coding protein that is expressed in a variety of tissues. It is primarily localized to the nucleosome, which is the basic unit of chromatin. The HMG domain of HMGN2 is able to interact with the nucleosome, helping to regulate the stability of chromatin. It is also involved in the regulation of DNA binding and cell signaling pathways. While there are currently no drugs that are specifically targeting HMGN2, new studies are being done to better understand its role in the regulation of chromatin structure and gene expression.

Protein Name: High Mobility Group Nucleosomal Binding Domain 2

Functions: Binds to the inner side of the nucleosomal DNA thus altering the interaction between the DNA and the histone octamer. May be involved in the process which maintains transcribable genes in a unique chromatin conformation (By similarity)

The "HMGN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HMGN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets